45
Participants
Start Date
March 26, 2019
Primary Completion Date
February 10, 2021
Study Completion Date
February 10, 2021
p24CE1/2 pDNA vaccine
4 mg administered by one injection/electroporation
p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine
2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55\^gag pDNA administered by one injection/electroporation
Full-length p55^gag pDNA vaccine
4 mg full-length p55\^gag pDNA vaccine administered by one injection/electroporation
Placebo
1 mL placebo administered by one injection/electroporation
University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester
University of Pittsburgh CRS, Pittsburgh
Penn Therapeutics, CRS, Philadelphia
Chapel Hill CRS, Chapel Hill
Alabama CRS, Birmingham
Vanderbilt Therapeutics (VT) CRS, Nashville
Ohio State University CRS, Columbus
Northwestern University CRS, Chicago
Rush University CRS, Chicago
UCLA CARE Center CRS, Los Angeles
Ucsf Hiv/Aids Crs, San Francisco
Massachusetts General Hospital CRS (MGH CRS), Boston
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston
University of Washington AIDS CRS, Seattle
Puerto Rico AIDS Clinical Trials Unit CRS, San Juan
National Institute of Allergy and Infectious Diseases (NIAID)
NIH